Chris Shibutani

Eli Lilly Stock Eyes Worst Month Since February 2009: Is It Time To Buy The Dip?

Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug

Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings

Eli Lilly's Q2 Sales Surge 36%, Analysts Cautious On Future Supply, Market Dynamics; Optimistic About Next-Gen Oral Weight-Loss Drug

Is Bristol-Myers Squibb's Stock Rally Justified? Bull Vs. Bear Analysts On Q2 Earnings

This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate

This Pfizer Analyst Is Turning Bullish Citing 'Pipeline Progress And M&A Activity'

This United Therapeutics Analyst Is No Longer Bearish, Expects Mid-Decade $4B Revenue Run Rate

This Pfizer Analyst Is Turning Bullish Citing 'Pipeline Progress And M&A Activity'

Most Analysts Defend Esperion As Shares Sell Off Sharply

With EU Approval For Puma Biotech's Breast Cancer Drug Unlikely, Cowen Downgrades

Chris Shibutani Recent News